-
Mashup Score: 20New CAR-T cells offer on-demand control for cancer treatment - 9 month(s) ago
Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer immunotherapy—that can be switched on to varying degrees of intensity and then …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 6GPC2 CAR T-cells as a potential therapeutic strategy for intraocular and CNS metastatic retinoblastomas - 9 month(s) ago
Pascual-Pasto G, McIntyre B, Giudice AM, et al. Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas With Local and Systemic Delivery of CAR T-Cells. Clinical Cancer Research. 2024;…
Source: www.astct.orgCategories: General Medicine News, Oncologists1Tweet-
Research with human samples and mouse models found that chimeric antigen receptor (CAR) T-cells aimed at glypican-2 (GPC2) could delay ocular loss in patients with metastatic retinoblastoma. Read more on Nucleus: https://t.co/TVX7nBOYbM #CARTcells @AACR https://t.co/FG8a3mAKdB
-
-
Mashup Score: 6GPC2 CAR T-cells as a potential therapeutic strategy for intraocular and CNS metastatic retinoblastomas - 9 month(s) ago
Pascual-Pasto G, McIntyre B, Giudice AM, et al. Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas With Local and Systemic Delivery of CAR T-Cells. Clinical Cancer Research. 2024;…
Source: www.astct.orgCategories: General Medicine News, Oncologists1Tweet-
Research with human samples and mouse models found that chimeric antigen receptor (CAR) T-cells aimed at glypican-2 (GPC2) could delay ocular loss in patients with metastatic retinoblastoma. Read more on Nucleus: https://t.co/TVX7nBOYbM #CARTcells @AACR https://t.co/FG8a3mAKdB
-
-
Mashup Score: 6GPC2 CAR T-cells as a potential therapeutic strategy for intraocular and CNS metastatic retinoblastomas - 10 month(s) ago
Pascual-Pasto G, McIntyre B, Giudice AM, et al. Targeting GPC2 on Intraocular and CNS Metastatic Retinoblastomas With Local and Systemic Delivery of CAR T-Cells. Clinical Cancer Research. 2024;…
Source: www.astct.orgCategories: General Medicine News, Oncologists1Tweet-
Research with human samples and mouse models found that chimeric antigen receptor (CAR) T-cells aimed at glypican-2 (GPC2) could delay ocular loss in patients with metastatic retinoblastoma. Read more on Nucleus: https://t.co/TVX7nBOYbM #CARTcells @AACR https://t.co/FG8a3mAKdB
-
-
Mashup Score: 0A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia - 10 month(s) ago
Key Points. Combining CAR-T cells targeting CD19 & CD22 with a recombinant, polymer-conjugated IL15 receptor agonist (NKTR-255) was safe and feasible.2
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
SCI member @LoriMuffly & others found that combining #CARTcells targeting CD19 and CD22 with a recombinant, polymer-conjugated IL15 receptor agonist (NKTR-255) was safe & feasible. NKTR-255 was associated with increases in cytokines and related chemokines. https://t.co/PTNATz9N4K https://t.co/06XAbGh4av
-
-
Mashup Score: 11Evaluating real-world Outcomes, Access Barriers and Scientific Progress: Introduction to U.S. Myeloma Innovations Research Collaborative (USMIRC) Group - 11 month(s) ago
Advancements in medical research are constantly transforming oncology care, bringing new hopes to patients, and posing fresh challenges for clinicians. U.S. Myeloma Innovations Research…
Source: www.astct.orgCategories: General Medicine News, Oncologists1Tweet-
U.S. Myeloma Innovations Research Collaborative (USMIRC) group is a collaboration among seven academic institutions to publish real-world data on various aspects of multiple myeloma care, #CARTcells & other innovative treatments. Read more on Nucleus: https://t.co/evazjovQ6J https://t.co/HOuRjk4ly1
-
-
Mashup Score: 11Knockout of CD5 on CAR T cells shown to boost anti-tumor efficacy - 12 month(s) ago
The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for CD5, a protein found on …
Source: medicalxpress.comCategories: General Medicine News, General HCPsTweet-
Knockout of CD5 on #CARTCells shown to boost anti-tumor efficacy @pennmedicine @SciImmunology https://t.co/uel69PH3cb
-
-
Mashup Score: 3Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy - 1 year(s) ago
Although CAR-T cells have revolutionized the treatment of hematological malignancies, there are several important factors that must be addressed regarding…
Source: www.vjhemonc.comCategories: General Medicine News, Onc News and JournalsTweet-
This week's podcast is all things CAR-T! Tune in as experts Ulrich Jäger (@MedUni_Wien), @KRejeski (@MSKCancerCenter) & Gérard de Pouvourville (@essec) discuss: 👉The role of lymphodepletion 👉ICAHT pathogenesis 👉The cost effectiveness of #CARTcells 🎧 https://t.co/RiUE3rUAwH https://t.co/DUfvhbb7rO
-
-
Mashup Score: 1Hypoxia-Responsive CAR-T Cells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors - 1 year(s) ago
Engineering CAR-T cells to upregulate CAR expression under hypoxic conditions induces metabolic reprogramming, reduces differentiation, and increases proliferation to enhance their antitumor activity, providing a strategy to improve efficacy and safety.
Source: aacrjournals.orgCategories: General Medicine News, Onc News and JournalsTweet-
Read the article— Hypoxia-Responsive #CARTCells Exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors, by Xiuxiu Zhu et al. https://t.co/KZ3PY3WUjm https://t.co/EFCpGL1QMz
-
-
Mashup Score: 0CAR T-Cell Therapy with Drs. Gottschalk and Velasquez - 2 year(s) ago
December 28, 2023 32 min listen Add topic to email alerts Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In this…
Source: www.healio.comCategories: General Medicine News, Onc News and JournalsTweet-
In the latest episode of Oncology Overdrive: @StJudeResearch’s @PaulinaV_MD talks with host @ShikhaJainMD about the development of CAR T-cell therapy and what lies ahead for this research. #CARTcells Listen now: https://t.co/wkuhzWYazp https://t.co/1yCs8RoU26
-
New #CAR-#TCells offer on-demand control for cancer treatment @Ludwig_Cancer @PNASNews https://t.co/gJXnOgYjkb